Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pergolide
Drug ID BADD_D01735
Description Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.
Indications and Usage Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy.
Marketing Status approved; investigational; vet_approved; withdrawn
ATC Code N04BC02
DrugBank ID DB01186
KEGG ID D08339
MeSH ID D010479
PubChem ID 47811
TTD Drug ID D04JCN
NDC Product Code Not Available
UNII 24MJ822NZ9
Synonyms Pergolide | Pharken | Permax | Celance | Parkotil | LY-127809 | LY127809 | LY-127,809 | LY127,809 | Pergolide Mesylate | Mesylate, Pergolide
Chemical Information
Molecular Formula C19H26N2S
CAS Registry Number 66104-22-1
SMILES CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atrioventricular block02.03.01.002--Not Available
Back pain15.03.04.005--
Benign neoplasm of skin16.26.01.006; 23.10.01.006--Not Available
Bladder cancer20.03.04.001; 16.08.01.001--Not Available
Bladder pain20.02.02.001--Not Available
Blindness06.02.10.003; 17.17.01.003--Not Available
Blood uric acid increased13.02.04.001--Not Available
Body temperature decreased13.15.01.010--Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.001--
Bone sarcoma16.29.03.001; 15.09.03.001--Not Available
Bradycardia02.03.02.002--Not Available
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Breast engorgement21.05.05.002; 18.08.02.001--Not Available
Breast pain21.05.05.003--
Bronchitis22.07.01.001; 11.01.09.001--
Bursitis12.04.03.010; 15.04.01.001--Not Available
Cachexia16.32.03.011; 14.03.02.001; 08.01.01.009--Not Available
Calculus urinary20.04.03.002--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure congestive02.05.01.002--Not Available
Cataract06.06.01.001--
Cellulitis23.11.02.004; 11.02.01.001--Not Available
Cerebral haemorrhage17.08.01.003; 24.07.04.001--Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.005--
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Cervix carcinoma21.06.02.001; 16.12.01.001--Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.003--Not Available
Chills15.05.03.016; 08.01.09.001--
Cholecystitis09.03.01.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 11 Pages